National Institutes of Health

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology aimed at enhancing surgical outcomes. The company has developed a proprietary ultrasound-based platform that enables clinicians to detect anastomotic blood clots and assess critical intravascular flow metrics directly at the point of care. This technology not only facilitates the measurement of blood flow and vessel morphology but also includes bioresorbable and echogenic equipment to mark at-risk blood vessels for future assessments. By providing actionable data, Sonavex supports healthcare providers in monitoring and improving patient care, particularly in the context of post-operative complications.

The Mt. Saint Mary’s University in Emmitsburg, Maryland, offers quality undergraduate and graduate programs that allow for the intellectual and spiritual growth of every student. Its strong Roman Catholic identity informs nearly all aspects of the university, such as the curriculum, campus ministry and service organizations and class instruction. The university aims to aid all students in their spiritual journey, no matter to which faith they belong. The school sponsors many events designed for spiritual fulfillment, like retreats, community-based service projects and religious services. It also has an active student life, with more than 70 groups and organizations from student government to St. Mary’s own radio station. There’s always something to do on campus, whether you want to catch a performance of the Beijing Opera, hear a guest speaker or enjoy the Annual Crab Feast, which are only a few of the many opportunities St. Mary’s offers. Academics include traditional undergraduate programs in Biology, Environmental Science, Psychology, Theology and more. Available graduate programs are in Business Administration, Health Administration, Education and Teaching. Admissions require students to submit ACT or SAT scores, a letter of recommendation and a personal statement as well as have been involved in extracurricular activities. Many students who are accepted are eligible for academic scholarships. Other financial aid options include federal grants, loans, ROTC scholarships and work-study programs.

Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology aimed at enhancing surgical outcomes. The company has developed a proprietary ultrasound-based platform that enables clinicians to detect anastomotic blood clots and assess critical intravascular flow metrics directly at the point of care. This technology not only facilitates the measurement of blood flow and vessel morphology but also includes bioresorbable and echogenic equipment to mark at-risk blood vessels for future assessments. By providing actionable data, Sonavex supports healthcare providers in monitoring and improving patient care, particularly in the context of post-operative complications.

NextStep Robotics Inc. is focused on developing innovative solutions for treating foot drop through a robotic device that enhances walking function. Incorporated in 2017 and based in Baltimore, Maryland, the company enables clinics to offer personalized robotic therapy using adaptive software that provides assistance tailored to each patient's needs. This system allows lower-skilled clinic staff to operate the device, thereby freeing up therapists to concentrate on other treatment modalities. As the company collects more data, the software will evolve into an AI-based system that optimizes training protocols for individual patients. The device is classified as a Class 1 Exercise Device, which allows for immediate revenue generation through direct sales, leasing, software subscriptions, and service contracts. This clinically proven approach not only improves patient outcomes but also enables clinics to provide reimbursable therapy for conditions that previously lacked effective treatment options.

The Department of Veterinary Medicine, University of Maryland, College Park and the Maryland Campus of the Virginia-Maryland College of Veterinary Medicine (VMCVM) are integrated as a single unit housed in the Avrum Gudelsky Veterinary Center at the University of Maryland, College Park Campus.

The University of Maryland, established in 1856 and located in College Park, Maryland, has gained significant recognition as a leading public research university. Over the past two decades, it has enhanced its reputation through a strong focus on research, entrepreneurship, and innovation. The university is committed to advancing its competitive advantages and pursuing ambitious goals to solidify its standing among the world's top institutions. The executive management team oversees the university's assets, ensuring effective governance and strategic direction to support its mission.

CoapTech, Inc. is a medical device company based in Baltimore, Maryland, specializing in ultrasound-based solutions for the placement of feeding tubes. Founded in 2016, CoapTech has developed the Point-of-care Ultrasound Magnet Aligned (PUMA-G) System, which mitigates risks associated with traditional methods such as PEG blind sticks, endoscope reprocessing, and fluoroscopy by allowing for ultrasound visualization from the stomach wall to the surface. The company also offers a procedure known as Percutaneous Ultrasound Gastrostomy (PUG), designed for critical care physicians and non-surgical providers to simplify the insertion of gastrostomy tubes. Utilizing a proprietary technology called Coaptive Ultrasound, CoapTech combines magnetic device guidance with real-time ultrasound feedback, aiming to improve safety, reduce healthcare costs, and enhance patient care experiences. Their focus on the PUG procedure highlights a commitment to innovation, safety, and accessibility in medical care delivery across various patient populations.

Clear Guide's approach to interventional image guidance substantially reduces the footprint, simplifies the workflow, and reduces the cost of ultrasound-guided interventions. Clear Guide Medical, LLC is a privately-held company, based in Baltimore MD, USA, specializing in developing guidance systems for ultrasound-based medical interventions. We are a 2010 spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University.

Perceptive Navigation LLC is a pre-clinical stage medical device company based in Baltimore, Maryland, focused on developing interventional medical devices for image-guided surgery. Its flagship product, Vu-Path, is an innovative intracorporeal ultrasound device that combines forward-viewing ultrasound imaging with a working portal for the introduction of needles, biopsy instruments, guide wires, and therapeutic delivery. Designed to enhance the safety and efficacy of minimally invasive procedures across various medical specialties, including radiology, cardiology, interventional oncology, and urology, Vu-Path addresses critical limitations of existing imaging techniques, which can be costly, cumbersome, and risky. The device aims to provide accurate and precise access to internal structures, thereby reducing procedural times and enhancing overall patient care. By replacing traditional imaging methods like surface ultrasound, CT, X-Ray, and MRI, Vu-Path is positioned to streamline complex surgical operations while minimizing resource requirements. Perceptive Navigation was incorporated in 2012 and continues to advance its technology to meet the needs of the medical community.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases. Founded in 2011 and headquartered in Rockville, Maryland, the company is advancing a clinical-stage pipeline that includes therapies for inherited metabolic disorders, such as CERC-801, CERC-802, and CERC-803, which are focused on congenital disorders of glycosylation. Additionally, Cerecor is developing CERC-006, an oral mTOR inhibitor aimed at treating complex lymphatic malformations, and two monoclonal antibodies: CERC-002, targeting the cytokine LIGHT for severe pediatric-onset Crohn's disease, and CERC-007, targeting IL-18 for autoimmune inflammatory diseases like adult onset Still's disease and multiple myeloma. Several of these therapies have received Orphan Drug Designation and Rare Pediatric Disease Designation, qualifying them for expedited review upon FDA approval. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions.

Clear Guide's approach to interventional image guidance substantially reduces the footprint, simplifies the workflow, and reduces the cost of ultrasound-guided interventions. Clear Guide Medical, LLC is a privately-held company, based in Baltimore MD, USA, specializing in developing guidance systems for ultrasound-based medical interventions. We are a 2010 spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University.

The J. Craig Venter Institute is a prominent organization in genomic research, established in October 2006 through the merger of several institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the Institute operates from two primary locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The Institute's research initiatives span a wide range of topics, including genomic medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Notable achievements include the sequencing of the first free-living organism and significant contributions to the human genome project. Recent projects have involved sequencing microbial flora in human environments and discovering millions of new genes from ocean sampling expeditions. The Institute is also actively engaged in creating synthetic organisms and studying the evolution of infectious disease agents, aiming to enhance understanding and treatment of various diseases affecting global health.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's portfolio includes several investigational products, such as Margetuximab, a monoclonal antibody in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other candidates in development include MGA012 and MGD013, both targeting PD-1, as well as MGD019, which targets multiple immune checkpoints. MacroGenics is also advancing MGC018, an antibody-drug conjugate targeting B7-H3, and MGD014, a DART molecule designed for HIV-infected cells. The company has formed strategic collaborations with several organizations to enhance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics for cancer and other related diseases.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.